New gout drug epaminurad faces off against standard treatment in major trial

NCT ID NCT05815901

Completed Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested a new drug called epaminurad against the standard gout medication febuxostat in 612 adults with gout. The goal was to see if epaminurad could lower uric acid levels more effectively and safely. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epaminurad (a drug that lowers uric acid)
What this could lead to: If epaminurad works better than febuxostat, it could offer a new treatment option to control gout by lowering uric acid levels.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. Epaminurad may not be more effective or safer than existing drugs, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT

Contacts and locations

Locations

Inha University Hospital

Incheon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.